Abstract
Ocular insert (OI) has its wide recognition and importance from the 19th century around the world, the use of this dosage form in clinical practice was distributed throughout the USSR. The key issue covered in this review is the development of the ocular insert and their testing by specific parameters of quality. It is important to choose the right excipients and standardize ocular inserts according to pharmacopoeia articles (thickness, pH, biodegradation time). It is also important to control those indicators that increase patient compliance. Technology of solid dosage form consists of several stages: mixing, drying and cutting with packaging in primary polymer packaging. So the manufacturer does not need highly specialized equipment and staff skills. Based on this information, we can concluded that ocular inserts are promising and actively researched dosage form, which in the future, could fully complement or replace the medical drugs traditionally used in ophthalmology.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference55 articles.
1. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts–advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010 Jul;1(3):291-6. doi: 10.4103/0110-5558.72419, PMID 22247860.
2. Anshul S, Renu S. A review on levofloxacin in situ-gel formulation. Asian J Pharm Clin Res. 2015 Jan;8(1):37-41.
3. Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016 Dec 7;10:2433-41. doi: 10.2147/OPTH.S118409, PMID 27994437.
4. Aznabaev MT, Azamatova GA, Gya G. Ophthalmic medicinal films in the prevention of infectious and inflammatory complications. Saratov J Med Sci Res. 2018;14(4):933-8.
5. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013 Mar 13;29(2):106-23. doi: 10.1089/jop.2012.0200, PMID 23215539.